Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting AFP in Liver Cancer Biotech Investing
ALPHAEON Announces Results from Two Phase III Trials of DWP-450 Botulinum Toxin Type A Life Science Investing
Galapagos and MorphoSys initiate Phase 1 study in joint antibody program MOR106 Life Science Investing
SCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at 13th ASM Conference on Candida and Candidiasis Life Science Investing
Purdue Pharma Canada Expresses Disappointment in reaction to Health Canada decision to not proceed with proposed regulations requiring tamper resistance for Oxycodone Life Science Investing
Nivalis Therapeutics Reaches 50 Percent Enrollment Milestone in Phase 2 Clinical Trial in Cystic Fibrosis Pharmaceutical Investing
The Alliance for Regenerative Medicine and the International Society for Cellular Therapy Enter Into Memorandum of Understanding Life Science Investing
Gilead Sciences Announces Acquisition of Nimbus Therapeutics’ Acetyl-CoA Carboxlyase (ACC) Program for NASH and Other Liver Diseases Life Science Investing
Akari Therapeutics Announces Positive Preliminary Results from First PNH Patient Treated With Coversin Biotech Investing
Results from Vericel’s Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T Presented Today at ACC and Published in The Lancet Life Science Investing
Theravance Biopharma to Present New Data Demonstrating Potent in vitro Activity for VIBATIV(R) (telavancin) Against Difficult-to-Treat Infections, Including MRSA, at 2016 ECCMID Conference Life Science Investing
